1. Scrip
  2. >>Business
  3. >>Earnings

Lilly Preparing For Increasing Mounjaro Demand On Top Of Solid Launch

 
• By Joseph Haas

The pharma is increasing its manufacturing capacity for tirzepatide, mindful of its potential in a second indication of obesity and the supply issues faced by competitor Novo Nordisk.

Eli Lilly logo sign atop Lilly Biotechnology Center campus of an American pharmaceutical company Eli Lilly and Company
Tirzepatide may soon compete with semaglutide in two major indications • Source: Shutterstock

Launch metrics for Eli Lilly and Company’s GIP/GLP-1 analog Mounjaro (tirzepatide) in type 2 diabetes are exceeding expectations to this point, and the pharma reported during its 1 November earnings call that commercial coverage in the US increased significantly during the third quarter. Perhaps mindful of the supply issues faced by competitor Novo Nordisk A/S with Ozempic/Wegovy (semaglutide), Lilly is trying to prepare for high demand for the product in two major indications ahead of the planned submission for obesity in 2023.

The GIP/GLP-1 analog launched during the second quarter and brought in $187.3m during Q3, comprised of $97.3m in domestic sales and $90m in revenue sharing from Japanese commercialization partner Mitsubishi Tanabe Pharma Corporation. (Also see "Lilly’s Mounjaro Diabetes Approval Is First Challenge To Novo’s GLP-1 Franchise" - Scrip, 13 May, 2022

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

More from Business

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.